Akero Therapeutics

Akero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with serious metabolic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH), a severe form of non-alcoholic fatty liver disease. Their lead program, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein designed to mimic the balanced biological activity of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism. EFX is currently in Phase 3 clinical trials evaluating its efficacy and safety for the treatment of MASH.

Akero is headquartered in South San Francisco, California and boasts a team of experienced biopharma industry veterans. Their commitment to innovative science and a supportive, inclusive culture has earned them recognition as a company with strong growth potential and a focus on making a positive impact on patients' lives.

Akero Therapeutics emphasizes work-life balance and offers a flexible work schedule and location. They were largely virtual even before the COVID-19 pandemic, and believe employees perform best when they're at their best, regardless of location. This means employees can work remotely or from their San Francisco Bay Area office, allowing for a personalized work environment.

Akero Therapeutics offers a comprehensive benefits package that includes 100% employer-paid premiums for medical, dental, and vision insurance. All employees receive four weeks of paid vacation annually, in addition to federal holidays. Akero provides up to 16 weeks of paid family leave for new parents and encourages a flexible work schedule and location, allowing employees to work remotely. They also offer stock ownership options and a 401(k) plan.

Akero Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with serious metabolic diseases marked by high unmet medical need. Their primary focus is on metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease caused by metabolic dysregulation. Akero is pioneering novel therapies, like their lead candidate efruxifermin (EFX), to transform the lives of people living with these conditions.

Akero Therapeutics promotes a collaborative and inclusive culture that values diverse expertise and empowers employees to think boldly and challenge the status quo. The company fosters a supportive environment where individuals can grow professionally and personally, with a focus on teamwork, innovation, and a commitment to improving patients' lives.

Akero Therapeutics fosters a diverse and inclusive workplace where individuals from various backgrounds are valued and empowered to contribute their unique perspectives. They champion the diverse expertise of their team members, tackling challenges together with humility, transparency, and camaraderie. Akero's commitment to equity is evident in their comprehensive benefits package, which includes equal access to top-quality medical, dental, and vision benefits for all employees, as well as generous paid vacation, family leave, and flexible work arrangements. This commitment to fostering a diverse and inclusive environment allows Akero to attract and retain top talent, ultimately leading to the development of innovative therapies to improve the lives of patients.